The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel’s active metabolite
Atsuhiro Sugidachi(Daiichi Sankyo (United Kingdom)), Fumitoshi Asai(Azabu University), Katsunobu Hagihara(Daiichi-Sankyo (Japan)), Taketoshi Ogawa(Biomedical Research Laboratories (United States)), Masami Hashimoto(Daiichi-Sankyo (Japan)), Y. Niitsu(Daiichi-Sankyo (Japan)), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Atsushi Kurihara(Daiichi-Sankyo (Japan))
Cited by 220
Related Papers
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617